Table 3.

Characteristics of the 94 children included in the final analysis^* for each condition in the clinical trial.

	Xyl-2X	Xyl-3X	Control	Total
N (Laura/Delap)	33 (11/22)	32 (10/22)	29 (9/20)	94 (30/64)
Female sex – no. (%)	19 (57.8%)	18 (56.2%)	14 (48.3%)	51 (54.3%)
Age at randomization – months ± SD†	15.9 ± 2.6	13.7 ± 2.4	15.6 ± 2.7	15.0 ± 2.7
Follow-up time‡ – months ± SD	10.4 ± 2.5	10.6 ± 1.9	10.6 ± 2.1	10.5 ± 2.2

^*94 children had at least one exam follow-up exam during the study period and were included in this intent-to-treat analysis. Of these, 84 completed all follow-up exams and 10 who dropped out after having an interim exam.

^†SD= Standard Deviation

^‡Syrup randomization follow-up period was 12 months. However, some of the 94 children included in the analysis dropped out after their interim exam and thus reduced the mean follow-up time.